OMICmAge

OMICmAge is a multi-omics biological age biomarker published by Chen et al. in Nature Aging in februari 2026 [1]. The design goal was to combine three information layers that older clocks used separately: DNA methylation from blood, standard clinical labs like albumin and CRP, and structured electronic medical record data such as diagnoses and medications. This should give a more disease-anchored biological age than a methylation-only clock like Horvath or a lab-anchored clock like PhenoAge.

The clock is built and marketed by TruDiagnostic and is available as a direct-to-consumer add-on to their epigenetic-age panel, alongside DunedinPACE, GrimAge, and PhenoAge. The 2026 Nature Aging paper reports that OMICmAge outperforms first- and second-generation epigenetic clocks in predicting all-cause mortality, incident cardiovascular disease, and time-to-onset of multiple chronic conditions in the validation cohorts used [1]. Independent replication in a separate cohort published outside TruDiagnostic was not yet available as of mid-2026, so treat comparative claims cautiously.

Measurement uses a blood spot or venous blood sample processed on an Illumina methylation array, combined with clinical lab panel data and diagnostic codes when available. Direct-to-consumer pricing at TruDiagnostic sits in the range of a typical epigenetic clock panel, roughly 200 to 500 USD, though pricing changes; verify with the vendor.

No controlled human trial has yet shown that a specific intervention lowers OMICmAge more than a comparator clock. Because OMICmAge weights on inflammatory and metabolic labs plus disease codes, interventions that improve those inputs, like weight loss, glycemic control, or blood-pressure reduction, should plausibly move the score. This is inferred from the training inputs rather than demonstrated in a dedicated RCT with OMICmAge as an endpoint.

Caveats. This is a vendor-developed clock and its validation studies are led by researchers affiliated with TruDiagnostic. That is not disqualifying but it lowers the evidence tier until independent groups replicate the mortality and disease predictions in cohorts outside the training set. The EMR-derived features also mean the score is partly a function of health-system contact and coding quality, which varies by country and provider. There is no US FDA clearance for clinical use.

The plain takeaway: OMICmAge is a research-quality multi-omics biological age score with one strong Nature Aging paper claiming better prediction than earlier epigenetic clocks. It is available as a direct-to-consumer test through TruDiagnostic. Independent replication and controlled intervention trials are missing.